Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 27

1.

Maintaining Adherence Programme: evaluation of an innovative service model.

Lewis L, O'Keeffe C, Smyth I, Mallalieu J, Baldock L, Oliver S.

BJPsych Bull. 2016 Feb;40(1):5-11. doi: 10.1192/pb.bp.114.048496.

2.

Psychoeducation Improves Compliance and Outcome in Schizophrenia Without an Increase of Adverse Side Effects: A 7-Year Follow-up of the Munich PIP-Study.

Bäuml J, Pitschel-Walz G, Volz A, Lüscher S, Rentrop M, Kissling W, Jahn T.

Schizophr Bull. 2016 Jul;42 Suppl 1:S62-70. doi: 10.1093/schbul/sbw008. Epub 2016 Mar 8.

PMID:
26955982
3.

Getting less of what you want: reductions in statistical power and increased bias when categorizing medication adherence data.

Tueller SJ, Deboeck PR, Van Dorn RA.

J Behav Med. 2016 Feb 27. [Epub ahead of print]

PMID:
26921166
4.

Nurses' perceptions of medication adherence in schizophrenia: results of the ADHES cross-sectional questionnaire survey.

Emsley R, Alptekin K, Azorin JM, Cañas F, Dubois V, Gorwood P, Haddad PM, Naber D, Olivares JM, Papageorgiou G, Roca M, Thomas P, Hargarter L, Schreiner A; EMEA ADHES group.

Ther Adv Psychopharmacol. 2015 Dec;5(6):339-50. doi: 10.1177/2045125315612013.

5.

Cost-Effectiveness of Financial Incentives to Promote Adherence to Depot Antipsychotic Medication: Economic Evaluation of a Cluster-Randomised Controlled Trial.

Henderson C, Knapp M, Yeeles K, Bremner S, Eldridge S, David AS, O'Connell N, Burns T, Priebe S.

PLoS One. 2015 Oct 8;10(10):e0138816. doi: 10.1371/journal.pone.0138816. eCollection 2015.

6.

Adherence and rehospitalizations in patients with schizophrenia: evidence from Japanese claims data.

Kuwabara H, Saito Y, Mahlich J.

Neuropsychiatr Dis Treat. 2015 Apr 1;11:935-40. doi: 10.2147/NDT.S81677. eCollection 2015.

7.

Approaches to improve adherence to pharmacotherapy in patients with schizophrenia.

Shuler KM.

Patient Prefer Adherence. 2014 May 14;8:701-14. doi: 10.2147/PPA.S59371. eCollection 2014. Review.

8.

Risperidone long-acting injection in the treatment of schizophrenia: 24-month results from the electronic Schizophrenia Treatment Adherence Registry in Canada.

Williams R, Chandrasena R, Beauclair L, Luong D, Lam A.

Neuropsychiatr Dis Treat. 2014 Feb 27;10:417-25. doi: 10.2147/NDT.S54740. eCollection 2014.

9.

Village doctor-assisted case management of rural patients with schizophrenia: protocol for a cluster randomized control trial.

Gong W, Xu D, Zhou L, Brown HS 3rd, Smith KL, Xiao S.

Implement Sci. 2014 Jan 16;9:13. doi: 10.1186/1748-5908-9-13.

10.

Evaluation of a discharge medication service on an acute psychiatric unit.

Tomko JR, Ahmed N, Mukherjee K, Roma RS, Dilucente D, Orchowski K.

Hosp Pharm. 2013 Apr;48(4):314-20. doi: 10.1310/hpj4804-314.test.

11.

Medication adherence in schizophrenia: factors influencing adherence and consequences of nonadherence, a systematic literature review.

Higashi K, Medic G, Littlewood KJ, Diez T, Granström O, De Hert M.

Ther Adv Psychopharmacol. 2013 Aug;3(4):200-18. doi: 10.1177/2045125312474019.

12.

Effectiveness of financial incentives to improve adherence to maintenance treatment with antipsychotics: cluster randomised controlled trial.

Priebe S, Yeeles K, Bremner S, Lauber C, Eldridge S, Ashby D, David AS, O'Connell N, Forrest A, Burns T.

BMJ. 2013 Oct 7;347:f5847. doi: 10.1136/bmj.f5847.

13.

The personal, societal, and economic burden of schizophrenia in the People's Republic of China: implications for antipsychotic therapy.

Montgomery W, Liu L, Stensland MD, Xue HB, Treuer T, Ascher-Svanum H.

Clinicoecon Outcomes Res. 2013 Aug 14;5:407-18. doi: 10.2147/CEOR.S44325. eCollection 2013.

14.

Psychiatrists' awareness of partial and nonadherence to antipsychotic medication in schizophrenia: results from an Asia-Pacific survey.

Olivares JM, Thirunavukarasu M, Kulkarni J, Zhang HY, Zhang M, Zhang F.

Neuropsychiatr Dis Treat. 2013;9:1163-70. doi: 10.2147/NDT.S49080. Epub 2013 Aug 12.

15.

Cost-effectiveness of adherence therapy versus health education for people with schizophrenia: randomised controlled trial in four European countries.

Patel A, McCrone P, Leese M, Amaddeo F, Tansella M, Kilian R, Angermeyer M, Kikkert M, Schene A, Knapp M.

Cost Eff Resour Alloc. 2013 May 25;11(1):12. doi: 10.1186/1478-7547-11-12.

16.

Systematic review of the economic aspects of nonadherence to antipsychotic medication in patients with schizophrenia.

Dilla T, Ciudad A, Alvarez M.

Patient Prefer Adherence. 2013 Apr 4;7:275-84. doi: 10.2147/PPA.S41609. Print 2013.

17.
18.

Attitudes towards the administration of long-acting antipsychotics: a survey of physicians and nurses.

Geerts P, Martinez G, Schreiner A.

BMC Psychiatry. 2013 Feb 17;13:58. doi: 10.1186/1471-244X-13-58.

19.
20.

The management of schizophrenia: focus on extended-release quetiapine fumarate.

Peuskens J.

Neuropsychiatr Dis Treat. 2011;7:549-64. doi: 10.2147/NDT.S3380. Epub 2011 Sep 21.

Items per page

Supplemental Content

Write to the Help Desk